12
Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
Explore Our Brands
- WSJ
- Barron's
- MarketWatch
- IBD
- Buy Side from WSJ
Apple Inc.
NasdaqGS
AAPL
288.7
USD
5.82USD
(2.16%)
Microsoft Corporation
NasdaqGS
MSFT
508.96
USD
2.68USD
(0.53%)
Amazon.com, Inc.
NasdaqGS
AMZN
249.24
USD
0.7USD
(0.28%)
WSJ Membership
- The Journal Collection
- Subscription Options
- Why Subscribe?
- Corporate Subscriptions
- WSJ Higher Education Program
- WSJ High School Program
- Public Library Program
- WSJ Live
- Commercial Partnerships
Customer Service
- Customer Center
- Contact Us
- Cancel My Subscription
Tools & Features
- Newsletters & Alerts
- Guides
- Topics
- My News
- RSS Feeds
- Video Center
- Watchlist
- Podcasts
- Visual Stories
Ads
- Advertise
- Commercial Real Estate Ads
- Place a Classified Ad
- Sell Your Business
- Sell Your Home
- Recruitment & Career Ads
- Digital Self Service
More
- About Us
- Content Partnerships
- Corrections
- Jobs at WSJ
- News Archive
- Register for Free
- Reprints & Licensing
- Buy Issues
- WSJ Shop
- Dow Jones Press Room
- Dow Jones Smart Money
